Literature DB >> 32366602

Characterising HIV and STIs among transgender female sex workers: a longitudinal analysis.

Tonia Poteat1,2, Rebecca Hamilton White3, Katherine H A Footer3, Ju Nyeong Park3, Noya Galai2, Steven Huettner4, Brad E Silberzahn3,5, Sean T Allen3, Jennifer Glick3, S Wilson Beckham3, Charlotte A Gaydos6, Susan G Sherman3.   

Abstract

OBJECTIVES: Though highly vulnerable to HIV and STIs, transgender female sex workers (TFSWs) are understudied in the US HIV and STI response. This study examined the correlates of laboratory-confirmed STIs among a cohort of 62 TFSWs followed over the course of 1 year and explored associations between specimen site and self-reported engagement in insertive and receptive anal intercourse.
METHODS: Participants completed an interviewer-administered computer-assisted personal interview at baseline, 3-, 6-, 9- and 12-month visits where self-administered anal swabs and urine samples for gonorrhea, chlamydia and trichomoniasis were also collected. HIV testing was conducted at baseline, 6-month and 12-month visits.
RESULTS: Baseline HIV prevalence was 40.3% with no HIV seroconversions over follow-up. Baseline prevalence of gonorrhea, chlamydia and trichomoniasis was 9.7%, 17.7% and 14.5%, respectively. In the multivariable regression modelling, recent arrest was significantly associated with testing positive for any STI (adjusted risk ratio (RR) 1.77; 95% CI: 1.10 to 2.84). Insertive anal sex with clients was associated with increased risk of testing positive for an STI via urine specimen (RR 3.48; 95% CI: 1.14 to 10.62), while receptive anal sex was not significantly associated with specimen site.
CONCLUSION: Our findings confirm a high prevalence of STIs among TFSWs and highlight the importance of addressing structural drivers such as criminal justice involvement as well as the need to ensure screening for STIs at all anatomical sites regardless of self-reported sites of potential exposure. More research is needed to better understand HIV and STI vulnerabilities and appropriate interventions for TFSWs in the USA. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  chlamydia infection; commercial sex; gonorrhea; transgender; trichomoniasis

Mesh:

Year:  2020        PMID: 32366602      PMCID: PMC7769682          DOI: 10.1136/sextrans-2019-054414

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  25 in total

Review 1.  The performance of non-NAAT point-of-care (POC) tests and rapid NAAT tests for chlamydia and gonorrhoea infections. An assessment of currently available assays.

Authors:  Gary Brook
Journal:  Sex Transm Infect       Date:  2015-05-02       Impact factor: 3.519

2.  Rectal Trichomonas vaginalis infection in South African men who have sex with men.

Authors:  Charlotte M Hoffman; Lise Fritz; Oscar Radebe; Jan Henk Dubbink; James A McIntyre; Marleen M Kock; Remco Ph Peters
Journal:  Int J STD AIDS       Date:  2018-08-16       Impact factor: 1.359

3.  Comparison of the Cepheid GeneXpert CT/NG assay to the Hologic Aptima Combo2 assay for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in self-collected rectal swabs.

Authors:  Laura Dize; Barbara Silver; Charlotte Gaydos
Journal:  Diagn Microbiol Infect Dis       Date:  2017-10-26       Impact factor: 2.803

Review 4.  Global epidemiology of HIV among female sex workers: influence of structural determinants.

Authors:  Kate Shannon; Steffanie A Strathdee; Shira M Goldenberg; Putu Duff; Peninah Mwangi; Maia Rusakova; Sushena Reza-Paul; Joseph Lau; Kathleen Deering; Michael R Pickles; Marie-Claude Boily
Journal:  Lancet       Date:  2014-07-22       Impact factor: 79.321

5.  Pregnancy coercion, intimate partner violence and unintended pregnancy.

Authors:  Elizabeth Miller; Michele R Decker; Heather L McCauley; Daniel J Tancredi; Rebecca R Levenson; Jeffrey Waldman; Phyllis Schoenwald; Jay G Silverman
Journal:  Contraception       Date:  2010-01-27       Impact factor: 3.375

6.  Current research gaps: a global systematic review of HIV and sexually transmissible infections among transgender populations.

Authors:  Sarah MacCarthy; Tonia Poteat; Zhiyu Xia; Nicolette L Roque; Ashley Hyun Jin Kim; Stefan Baral; Sari L Reisner
Journal:  Sex Health       Date:  2017-10       Impact factor: 2.706

Review 7.  The global response and unmet actions for HIV and sex workers.

Authors:  Kate Shannon; Anna-Louise Crago; Stefan D Baral; Linda-Gail Bekker; Deanna Kerrigan; Michele R Decker; Tonia Poteat; Andrea L Wirtz; Brian Weir; Marie-Claude Boily; Jenny Butler; Steffanie A Strathdee; Chris Beyrer
Journal:  Lancet       Date:  2018-07-20       Impact factor: 79.321

8.  Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale).

Authors:  E M Andresen; J A Malmgren; W B Carter; D L Patrick
Journal:  Am J Prev Med       Date:  1994 Mar-Apr       Impact factor: 5.043

9.  Prevalence of rectal Trichomonas vaginalis and Mycoplasma genitalium in male patients at the San Francisco STD clinic, 2005-2006.

Authors:  Suzanna C Francis; Charlotte K Kent; Jeffrey D Klausner; Leah Rauch; Robert Kohn; Andrew Hardick; Charlotte A Gaydos
Journal:  Sex Transm Dis       Date:  2008-09       Impact factor: 2.830

10.  Drivers of HIV Infection Among Cisgender and Transgender Female Sex Worker Populations in Baltimore City: Results From the SAPPHIRE Study.

Authors:  Susan G Sherman; Ju Nyeong Park; Noya Galai; Sean T Allen; Steve S Huettner; Bradley E Silberzahn; Michele R Decker; Tonia C Poteat; Katherine H A Footer
Journal:  J Acquir Immune Defic Syndr       Date:  2019-04-15       Impact factor: 3.771

View more
  1 in total

1.  Increasing incidence rates of sexually transmitted infections from 2010 to 2019: an analysis of temporal trends by geographical regions and age groups from the 2019 Global Burden of Disease Study.

Authors:  Min Du; Wenxin Yan; Wenzhan Jing; Chenyuan Qin; Qiao Liu; Min Liu; Jue Liu
Journal:  BMC Infect Dis       Date:  2022-06-26       Impact factor: 3.667

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.